Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

NCT04882033 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Limited Stage

Interventions

DRUG: Concurrent chemoradiotherapy plus anlotinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital